Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.710
-0.016 (-2.20%)
At close: Feb 21, 2025, 4:00 PM
0.715
+0.005 (0.70%)
After-hours: Feb 21, 2025, 7:50 PM EST
Lexicon Pharmaceuticals Revenue
Lexicon Pharmaceuticals had revenue of $1.75M in the quarter ending September 30, 2024, with 980.25% growth. This brings the company's revenue in the last twelve months to $5.23M, up 886.60% year-over-year. In the year 2023, Lexicon Pharmaceuticals had annual revenue of $1.20M with 766.19% growth.
Revenue (ttm)
$5.23M
Revenue Growth
+886.60%
P/S Ratio
39.50
Revenue / Employee
$18,347
Employees
285
Market Cap
256.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
| Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
| Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
| Dec 31, 2020 | 24.00M | -298.08M | -92.55% |
| Dec 31, 2019 | 322.07M | 258.86M | 409.54% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
LXRX News
- 4 days ago - Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) - GlobeNewsWire
- 4 weeks ago - Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - GlobeNewsWire
- 7 weeks ago - Lexicon Appoints Scott Coiante as Chief Financial Officer - GlobeNewsWire
- 2 months ago - US FDA declines to approve Lexicon Pharma's add-on diabetes drug - Reuters
- 2 months ago - Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - GlobeNewsWire
- 3 months ago - Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - GlobeNewsWire
- 3 months ago - Lexicon Pharmaceuticals to Participate in December Investor Conferences - GlobeNewsWire
- 3 months ago - Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development - Reuters